These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21797732)

  • 1. Communicating BRCA1/2 genetic test results within the family: a qualitative analysis.
    Dancyger C; Wiseman M; Jacobs C; Smith JA; Wallace M; Michie S
    Psychol Health; 2011 Aug; 26(8):1018-35. PubMed ID: 21797732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems.
    Hallowell N; Ardern-Jones A; Eeles R; Foster C; Lucassen A; Moynihan C; Watson M
    Clin Genet; 2005 Jun; 67(6):492-502. PubMed ID: 15857416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experiences of BRCA1/2 Gene Mutation-Positive Women With Cancer in Communicating Genetic Risk to Their Relatives.
    Seven M; Shah LL; Daack-Hirsch S; Yazici H
    Cancer Nurs; 2021 May-Jun 01; 44(3):E142-E150. PubMed ID: 32022782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.
    Wagner Costalas J; Itzen M; Malick J; Babb JS; Bove B; Godwin AK; Daly MB
    Am J Med Genet C Semin Med Genet; 2003 May; 119C(1):11-8. PubMed ID: 12704633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
    Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
    Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching.
    Hallowell N; Foster C; Ardern-Jones A; Eeles R; Murday V; Watson M
    Genet Test; 2002; 6(2):79-87. PubMed ID: 12215246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell.
    Patenaude AF; Dorval M; DiGianni LS; Schneider KA; Chittenden A; Garber JE
    J Clin Oncol; 2006 Feb; 24(4):700-6. PubMed ID: 16446344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Information spreading about hereditary carriage of a BRCA1/2 mutation and ovarian cancer and rate of consultation of the concerned relatives].
    Christophe V; Leroy T; Adenis C; Reich M; Vennin P
    Bull Cancer; 2008 Apr; 95(4):395-402. PubMed ID: 18495568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Women receiving news of a family BRCA1/2 mutation: messages of fear and empowerment.
    Crotser CB; Dickerson SS
    J Nurs Scholarsh; 2010 Dec; 42(4):367-78. PubMed ID: 21091619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.
    van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A
    Patient Educ Couns; 2007 Jan; 65(1):58-68. PubMed ID: 16872788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
    Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
    Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Talking across generations: Family communication about BRCA1 and BRCA2 genetic cancer risk.
    Young AL; Butow PN; Rhodes P; Tucker KM; Williams R; Healey E; Wakefield CE
    J Genet Couns; 2019 Jun; 28(3):516-532. PubMed ID: 30694012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic genetic testing for hereditary breast and ovarian cancer in cancer patients: women's looking back on the pre-test period and a psychological evaluation.
    Claes E; Evers-Kiebooms G; Boogaerts A; Decruyenaere M; Denayer L; Legius E
    Genet Test; 2004; 8(1):13-21. PubMed ID: 15140370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.
    Derks-Smeets IA; Gietel-Habets JJ; Tibben A; Tjan-Heijnen VC; Meijer-Hoogeveen M; Geraedts JP; van Golde R; Gomez-Garcia E; van den Bogaart E; van Hooijdonk M; de Die-Smulders CE; van Osch LA
    Hum Reprod; 2014 May; 29(5):1103-12. PubMed ID: 24603131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Risk Information Sharing: The Experience of Individuals Receiving Genetic Counseling for BRCA1/2 Mutations.
    Chopra I; Kelly KM
    J Health Commun; 2017 Feb; 22(2):143-152. PubMed ID: 28112991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The phases of disclosing BRCA1/2 genetic information to offspring.
    Clarke S; Butler K; Esplen MJ
    Psychooncology; 2008 Aug; 17(8):797-803. PubMed ID: 18646247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic testing and familial implications in breast-ovarian cancer families.
    Oosterwijk JC; de Vries J; Mourits MJ; de Bock GH
    Maturitas; 2014 Aug; 78(4):252-7. PubMed ID: 24894332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.